JD Esq - SIGA Technologies General Counsel
| SIGA Stock | USD 7.31 0.83 12.81% |
Executive
JD Esq is General Counsel of SIGA Technologies
| Age | 56 |
| Address | 31 East 62nd Street, New York, NY, United States, 10065 |
| Phone | 212 672 9100 |
| Web | https://www.siga.com |
SIGA Technologies Management Efficiency
The company has return on total asset (ROA) of 0.3695 % which means that it generated a profit of $0.3695 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.5839 %, meaning that it created $0.5839 on every $100 dollars invested by stockholders. SIGA Technologies' management efficiency ratios could be used to measure how well SIGA Technologies manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.28. The current year's Return On Capital Employed is expected to grow to 0.44. At present, SIGA Technologies' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 23.1 M, whereas Non Currrent Assets Other are forecasted to decline to about 2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Darin Esq | Neurocrine Biosciences | 58 | |
| Kristen JD | Pacira BioSciences, | 50 | |
| Robert Cavorsi | Organogenesis Holdings | 45 | |
| Sumera Hasham | Dr Reddys Laboratories | N/A | |
| John Shulman | Petros Pharmaceuticals | 61 | |
| Matthew CPA | Neurocrine Biosciences | 44 | |
| Darin Lippoldt | Neurocrine Biosciences | 58 | |
| Lauren Riker | Pacira BioSciences, | 45 | |
| Jennifer PharmD | Avadel Pharmaceuticals PLC | N/A | |
| Christopher MD | Collegium Pharmaceutical | N/A | |
| Jason Vaughn | Avadel Pharmaceuticals PLC | N/A | |
| Jayanth Sridhar | Dr Reddys Laboratories | 53 | |
| Peter Norman | Alkermes Plc | N/A | |
| Jana Noeldeke | Ironwood Pharmaceuticals | N/A | |
| Richa Periwal | Dr Reddys Laboratories | N/A | |
| John MBA | Catalent | 69 | |
| Sushrut Kulkarni | Dr Reddys Laboratories | 54 | |
| Deepak Sapra | Dr Reddys Laboratories | 45 | |
| Christopher Young | Pacira BioSciences, | 52 | |
| Jane Sorensen | Neurocrine Biosciences | N/A | |
| Mannam Venkatanarasimham | Dr Reddys Laboratories | N/A | |
Management Performance
| Return On Equity | 0.58 | ||||
| Return On Asset | 0.37 |
SIGA Technologies Leadership Team
Elected by the shareholders, the SIGA Technologies' board of directors comprises two types of representatives: SIGA Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SIGA. The board's role is to monitor SIGA Technologies' management team and ensure that shareholders' interests are well served. SIGA Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SIGA Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jay MD, Chief VP | ||
| Tove Bolken, Senior Officer | ||
| Herb Vloedman, Senior Officer | ||
| III MD, CEO Director | ||
| JD Esq, General Counsel | ||
| Daniel CPA, CFO VP | ||
| Dennis Hruby, Chief Scientific Officer and VP | ||
| Daniel Luckshire, CFO, Principal Accounting Officer, Executive VP and Secretary | ||
| Diem MBA, CEO Director |
SIGA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SIGA Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.58 | ||||
| Return On Asset | 0.37 | ||||
| Profit Margin | 0.49 % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 363.97 M | ||||
| Shares Outstanding | 71.4 M | ||||
| Shares Owned By Insiders | 43.23 % | ||||
| Shares Owned By Institutions | 50.66 % | ||||
| Number Of Shares Shorted | 4.57 M | ||||
| Price To Earning | 12.41 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether SIGA Technologies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of SIGA Technologies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Siga Technologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Siga Technologies Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SIGA Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For information on how to trade SIGA Stock refer to our How to Trade SIGA Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of SIGA Technologies. If investors know SIGA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about SIGA Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.721 | Earnings Share 1.17 | Revenue Per Share 2.441 | Quarterly Revenue Growth 0.084 | Return On Assets 0.3695 |
The market value of SIGA Technologies is measured differently than its book value, which is the value of SIGA that is recorded on the company's balance sheet. Investors also form their own opinion of SIGA Technologies' value that differs from its market value or its book value, called intrinsic value, which is SIGA Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because SIGA Technologies' market value can be influenced by many factors that don't directly affect SIGA Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between SIGA Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if SIGA Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SIGA Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.